

Daniel S Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/40909/publications.pdf>

Version: 2024-02-01

56
papers

33,075
citations

109137

35
h-index

205818

48
g-index

57
all docs

57
docs citations

57
times ranked

36422
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncology Meets Immunology: The Cancer-Immunity Cycle. <i>Immunity</i> , 2013, 39, 1-10.	6.6	4,815
2	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014, 515, 563-567.	13.7	4,342
3	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet</i> , The, 2017, 389, 255-265.	6.3	3,872
4	Elements of cancer immunity and the cancer's immune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
5	TGF β 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.	13.7	3,359
6	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1837-1846.	6.3	2,390
7	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature</i> , 2014, 515, 558-562.	13.7	2,109
8	VEGF in Signaling and Disease: Beyond Discovery and Development. <i>Cell</i> , 2019, 176, 1248-1264.	13.5	1,468
9	Top 10 Challenges in Cancer Immunotherapy. <i>Immunity</i> , 2020, 52, 17-35.	6.6	1,177
10	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
11	Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. <i>Nature Communications</i> , 2016, 7, 12624.	5.8	550
12	Molecular Pathways: Next-Generation Immunotherapy's Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. <i>Clinical Cancer Research</i> , 2012, 18, 6580-6587.	3.2	543
13	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <i>Annals of Oncology</i> , 2016, 27, 1492-1504.	0.6	460
14	T cells use two directionally distinct pathways for cytokine secretion. <i>Nature Immunology</i> , 2006, 7, 247-255.	7.0	396
15	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 850-858.	0.8	288
16	Molecular Biomarker Analyses Using Circulating Tumor Cells. <i>PLoS ONE</i> , 2010, 5, e12517.	1.1	271
17	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	229
18	A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. <i>Translational Oncology</i> , 2012, 5, 404-407.	1.7	220

#	ARTICLE	IF	CITATIONS
19	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10119-E10126.	3.3	180
20	Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab. Clinical Cancer Research, 2013, 19, 929-937.	3.2	179
21	BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology, 2012, 30, 34-41.	0.8	172
22	Combinations of Bevacizumab With Cancer Immunotherapy. Cancer Journal (Sudbury, Mass), 2018, 24, 193-204.	1.0	144
23	Detection and Characterization of Cellular Immune Responses Using Peptide-MHC Microarrays. PLoS Biology, 2003, 1, e65.	2.6	131
24	Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Research, 2015, 75, 2859-2859.	0.4	128
25	Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 2012, 366, 2035-2036.	13.9	122
26	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).. Journal of Clinical Oncology, 2013, 31, 9010-9010.	0.8	118
27	A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. Journal of Clinical Oncology, 2013, 31, 3000-3000.	0.8	116
28	Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 372-381.	3.2	89
29	A pregnancy-specific glycoprotein is expressed in the brain and serves as a receptor for mouse hepatitis virus.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 12095-12099.	3.3	85
30	Marked Differences in Human Melanoma Antigen-Specific T Cell Responsiveness after Vaccination Using a Functional Microarray. PLoS Medicine, 2005, 2, e265.	3.9	77
31	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
32	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research, 2019, 25, 6061-6072.	3.2	58
33	Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies. Clinical Cancer Research, 2013, 19, 3681-3692.	3.2	53
34	Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2014, 32, 5011-5011.	0.8	49
35	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8008-8008.	0.8	44
36	Retroviral Vector-Mediated Transfer of an Antisense Cyclin G1 Construct Inhibits Osteosarcoma Tumor Growth in Nude Mice. Human Gene Therapy, 1997, 8, 1667-1674.	1.4	39

#	ARTICLE	IF	CITATIONS
37	Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. Journal of Clinical Investigation, 2013, 123, 3997-4009.	3.9	33
38	Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.. Journal of Clinical Oncology, 2013, 31, 3001-3001.	0.8	33
39	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunology Research, 2016, 4, 279-288.	1.6	29
40	Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Research, 2015, 75, PD1-6-PD1-6.	0.4	25
41	Association of PD-L2 expression in human tumors with atezolizumab activity.. Journal of Clinical Oncology, 2016, 34, 11506-11506.	0.8	22
42	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.. Journal of Clinical Oncology, 2013, 31, 3622-3622.	0.8	17
43	Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. Journal of Clinical Oncology, 2016, 34, 9028-9028.	0.8	16
44	Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. , 2013, , .		15
45	Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.. Journal of Clinical Oncology, 2016, 34, 9032-9032.	0.8	14
46	Mouse Hepatitis Virus Infection Induces an Early, Transient Calcium Influx in Mouse Astrocytoma Cells. Experimental Cell Research, 1997, 237, 55-62.	1.2	12
47	Cellular immunotherapy: antigen recognition is just the beginning. Seminars in Immunopathology, 2005, 27, 119-127.	4.0	11
48	New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31st Annual Meeting of the Society for Immunotherapy of Cancer, 2016. , 2017, 5, 50.		10
49	Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitinib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients. Cancer Research, 2017, 77, CT081-CT081.	0.4	9
50	Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.. Journal of Clinical Oncology, 2015, 33, 3015-3015.	0.8	9
51	Abstract 5664: A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release. , 2020, , .		3
52	Abstract 2979: A balance of genomic instability, tumor-immune contexture and TGF- β 2 signaling contributing to exclusion of T cells governs response to PD-L1 checkpoint blockade. , 2018, , .		1
53	Introduction by the Guest Editors. Cancer Journal (Sudbury, Mass), 2018, 24, 163-164.	1.0	0
54	Abstract 5130: Neuropilin-1 expression in breast, colorectal and lung cancer. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
55	Anti-Angiogenesis Therapy in Melanoma. , 2012, , 155-184.		0
56	Abstract 1385: Molecular changes in breast tumors following bevacizumab-based treatment: Final analysis of a randomized neoadjuvant study of bevacizumab or placebo, followed by chemotherapy with or without bevacizumab, in patients with stage II or III breast cancer. , 2012, , .		0